김현석 (Cedars-Sinai Medical Center) | 한빛사논문 > 한빛사

한빛사논문

조회92

Cedars-Sinai Medical Center

CV File

Clin. Gastroenterol. Hepatol., Jul 01 2026, S1542-3565(26)00404-0 | https://doi.org/10.1016/j.cgh.2026.04.035 Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank

Hyun-Seok Kim ^{1 *}, Mohammad Saeid Rezaee-Zavareh ², Yufeng Wang ³, Abdelrahman M. Attia ¹, Minsun Kwak ¹, Seungwon Burm ¹, Derin Celtik¹, Daniel Legaspi ¹, Osama Khattab ¹, Naomy Kim ¹, Beza M. Mengistu ³, Kelsey N. Larios ³, David Sooik Kim ^4,5, Walid Ayoub ¹, Alexandar Kuo ¹, Paul Martin ¹, Aarshi Vipani ¹, Yun Wang ¹, Suthat Liangpunsakul ^6,7, Debiao Li ³, Shelly C. Lu ¹, Stephen Pandol ¹, Ju Dong Yang ^1,8

¹Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California
²Middle East Liver Diseases (MELD) Center, Tehran, Iran
³Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
⁴University of California Los Angeles Medical School, Los Angeles, California
⁵Department of Gastroenterology and Hepatology, University of Southern California, Los Angeles, California
⁶Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
⁷Roudebush Veterans Administration Medical Center, Indianapolis, Indiana
⁸Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California

^*Corresponding author: correspondence to Hyun-Seok Kim

Abstract

Background & Aims
Coffee consumption has been linked to a reduced risk of liver disease, but large-scale prospective studies integrating imaging biomarkers, proteomics, and intake patterns remain limited. The effects of coffee type, additives, and metabolic modifiers are also unclear.

Methods
We analyzed 354,957 UK Biobank participants without baseline cirrhosis or hepatocellular carcinoma. Coffee consumption, type (caffeinated/decaffeinated), and additives (sugar/sweeteners) were assessed by questionnaire. Incident cirrhosis, hepatocellular carcinoma, and liver-related mortality were ascertained through linked records. In a subcohort (n = 28,961) undergoing magnetic resonance imaging, hepatic fat (proton density fat fraction), iron, and fibroinflammation (iron-corrected T1) were evaluated. Proteomic profiling (n = 44,633) used Olink assays. Models were adjusted for demographic, behavioral, metabolic, and genetic covariates.

Results
Over a median 13-year follow-up, higher coffee intake showed a graded reduction in liver outcomes, with ≥5 cups/day group having risk reductions of cirrhosis (hazard ratio, 0.68; 95% confidence interval, 0.58–0.79), hepatocellular carcinoma (hazard ratio, 0.53; 95% confidence interval, 0.34–0.83), and liver-related mortality (hazard ratio, 0.58; 95% confidence interval, 0.45–0.74). Protective associations were similar for caffeinated and decaffeinated coffee and persisted among those adding sugar or artificial sweeteners, although additive use correlated with modestly higher iron-corrected T1. Higher coffee intake corresponded to lower hepatic fat, iron, and fibroinflammation. Proteomic analysis revealed consistent patterns: higher levels of hepatocellular synthesis and complement proteins (transthyretin, selenoprotein P, complement factor H-related protein4/5) and lower levels of fibrogenic and macrophage-activation markers (microfibril-associated protein 4, colony stimulating factor 1 receptor, ectonucleotide pyrophosphatase/phosphodiesterase 2, transthyretin) with coffee drinking.

Conclusions
Higher coffee intake was associated with favorable clinical, imaging, and proteomic indicators of liver health. These multidimensional findings support moderate unsweetened coffee as a simple strategy for liver disease prevention.

논문정보